CRDF - Cardiff Oncology - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

CRDF is currently covered by 2 analysts with an average price target of $12.25. This is a potential upside of $9.37 (325.35%) from yesterday's end of day stock price of $2.88.

Cardiff Oncology's activity chart (see below) currently has 13 price targets and 25 ratings on display. The stock rating distribution of CRDF is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 12.5% with an average time for these price targets to be met of 270 days.

Highest price target for CRDF is $13, Lowest price target is $10, average price target is $11.5.

Most recent stock forecast was given by JOSEPH CATANZARO from PIPER SANDLER on 13-Dec-2024. First documented stock forecast 08-Oct-2020.

Best performing analysts who are covering CRDF - Cardiff Oncology:

Joseph Catanzaro Raghuram Selvaraju Joel Beatty Naureen Quibria

Currently out of the existing stock ratings of CRDF, 7 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$10

$7.12 (247.22%)

$7

4 months 14 days ago
(13-Dec-2024)

1/6 (16.67%)

$6.08 (155.10%)

547

Buy

$13

$10.12 (351.39%)

$14

5 months 19 days ago
(08-Nov-2024)

0/5 (0%)

$9.92 (322.08%)

Buy

$5

$2.12 (73.61%)

$6

2 years 7 months ago
(27-Sep-2022)

1/3 (33.33%)

$3.45 (222.58%)

533

Buy

$25

$23.61 (1698.56%)

3 years 7 months 18 days ago
(09-Sep-2021)

0/1 (0%)

$18.01 (257.65%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is CRDF (Cardiff Oncology) average time for price targets to be met?

On average it took 270 days on average for the stock forecasts to be realized with a an average price target met ratio 12.5

Which analyst has the current highest performing score on CRDF (Cardiff Oncology) with a proven track record?

JOSEPH CATANZARO

Which analyst has the current lower performing score on CRDF (Cardiff Oncology) with a proven track record?

NAUREEN QUIBRIA

Which analyst has the most public recommendations on CRDF (Cardiff Oncology)?

Joseph Catanzaro works at PIPER SANDLER and has 9 price targets and 7 ratings on CRDF

Which analyst is the currently most bullish on CRDF (Cardiff Oncology)?

Naureen Quibria with highest potential upside - $23.61

Which analyst is the currently most reserved on CRDF (Cardiff Oncology)?

Joel Beatty with lowest potential downside - $2.12

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?